Czech National Bank Increases Stock Holdings in Gilead Sciences, Inc. $GILD

Czech National Bank boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 353,398 shares of the biopharmaceutical company’s stock after purchasing an additional 15,504 shares during the quarter. Czech National Bank’s holdings in Gilead Sciences were worth $44,648,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the period. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $25,000. Quattro Advisors LLC purchased a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $26,000. Wealth Preservation Advisors LLC grew its position in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at $28,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, above the roughly $7.4 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by HIV medicines and Trodelvy. GILD Q2 Earnings Beat
• Positive Sentiment: Management raised its HIV growth outlook to 9%–10% and highlighted rapid adoption of Yeztugo, its HIV prevention treatment. PrEP sales reportedly doubled to approximately $1 billion, supporting the view that HIV remains Gilead’s primary growth engine. Q2 Earnings Call Highlights
• Positive Sentiment: Several analysts remain constructive: Cantor Fitzgerald reiterated an Overweight rating with a $155 target, while Needham reaffirmed Buy with a $170 target. Gilead also declared its $0.82 quarterly dividend, providing continued income support.
• Neutral Sentiment: The quarter was described as operationally strong, but reported earnings guidance remains negative because of acquisition-related charges and elevated research spending. The company’s 2026 base-business sales outlook is approximately $29.8 billion–$30.1 billion.
• Negative Sentiment: Gilead posted a $6.75 per-share quarterly loss versus $2.01 of earnings a year earlier. The loss was driven largely by acquisition-related costs, increasing concern about near-term profitability despite the revenue beat. Strong Quarter Hidden Behind Ugly Earnings
• Negative Sentiment: MSD and Gilead discontinued a Phase III Trodelvy-Keytruda study after lacklustre interim data. The failure weakens expectations for expanding Trodelvy’s use in combination therapy and adds uncertainty to Gilead’s oncology growth strategy. Trodelvy-Keytruda Study Discontinued
• Negative Sentiment: Veklury sales continued to decline sharply, while AIDS Healthcare Foundation criticized Gilead’s HIV pricing and access policies. The controversy could create reputational or longer-term market-access risks. CEO Daniel O’Day’s planned sale of 15,000 shares was a minor additional negative signal.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GILD shares. Truist Financial dropped their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research note on Wednesday. Barclays lowered their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a report on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a report on Wednesday. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $130.86 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.14 and a quick ratio of 1.77. The firm has a market capitalization of $162.47 billion, a PE ratio of -49.01 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The business’s fifty day moving average price is $129.43 and its two-hundred day moving average price is $136.22.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the previous year, the company posted $2.01 earnings per share. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post -0.65 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is 44.69%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 82,000 shares of company stock worth $10,641,790. 0.30% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.